



# Biotech Daily

Tuesday January 24, 2023

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH UP: PATRYS UP 10%; NEUREN DOWN 4%**
- \* **VIVAZOME WINS \$3m FEDERAL CRC-P GRANT FOR EXOSOMES**
- \* **FDA APPROVES IMRICOR CARDIAC ABLATION TRIAL**
- \* **CRESO \$350k RECORD MARIJUANA ORDER; MANITOBA EXPANSION**
- \* **GENETIC TECHNOLOGIES IMPROVES COLORECTAL CANCER RISK TEST**
- \* **PIE FUNDS BELOW 5% OF PROBIOTEC**
- \* **WILLOUGHBY CAPITAL INCREASES, DILUTED TO 15.95% OF KAZIA**
- \* **YUUWA CAPITAL FUND DIVESTS 54m ADALTA SHARES; FUND WIND-UP**
- \* **RHINOMED M-D MICHAEL JOHNSON PAY RISE TO \$375k PA**
- \* **HERAMED APPOINTS KEITH KOBY NORTH AMERICAN HEAD**

## MARKET REPORT

The Australian stock market was up 0.44 percent on Tuesday January 24, 2023, with the ASX200 up 33.1 points to 7,490.4 points. Seventeen of the Biotech Daily Top 40 stocks were up, 14 fell, seven traded unchanged and two were untraded. All three Big Caps fell.

Patrys was the best, up 0.3 cents or 10 percent to 3.3 cents, with 6.4 million shares traded. Kazia climbed 8.3 percent; Atomo and Universal Biosensors were up more than five percent; Dimerix improved 3.45 percent; Actinogen, Amplia, Compumedics, Mesoblast, Oncosil and Pro Medicus rose more than two percent; Clinuvel, Nova Eye, Orthocell and Proteomics were up one percent or more; with Avita and Volpara up by less than one percent.

Neuren led the falls, down 31 cents or 3.65 percent to \$8.18, with 1.1 million shares traded. Imugene, Micro-X, Pharmaxis and Telix lost more than three percent; Cochlear shed 2.5 percent; Impedimed, Next Science and Polynovo were down more than one percent; with CSL, Cyclopharm, Genetic Signatures, Medical Developments, Nanosonics, Paradigm, Resmed and Starpharma down by less than one percent.

### VIVAZOME THERAPEUTICS PTY LTD

Vivazome says it has received a \$3.0 million Federal co-operative research centre projects (CRC-P) grant for “Customised exosomes - the future of regenerative medicine”. Vivazome said the grant was announced by the Federal Minister for Industry and Science Ed Husic and the program promoted “collaboration between small companies, large companies and academic institutions”.

The company said it would work with La Trobe University’s Dr Lesley Cheng, the University of Queensland’s Prof David Reutens, Australian National University: Prof Riccardo Natoli, Cytiva’s Prof Tim O’Meara and Seerpharma director Paul Kerr. Vivazome chief executive officer Dr David Haylock said the company was “absolutely delighted” with the Government support and to work with world-leading project partners. “Exosomes have great potential to treat a wide range of diseases, including traumatic brain injury and retinal disease,” Dr Haylock said.

“With the help of our partner organizations, we will establish an exosome manufacturing facility, optimize technologies and processes for manufacture of exosomes, develop customized exosome products with enhanced function, and generate proof of concept data for clinical indications in areas of significant unmet need - ophthalmic and neurological diseases,” Dr Haylock said.

Vivazome said that the work would begin “in early 2023 with a series of significant scientific, industrial and education milestones to be achieved by the end of 2025”.

Vivazome is a private company.

### IMRICOR MEDICAL SYSTEMS

Imricor says the US Food and Drug Administration has approved a 91-patient trial of its Vision-magnetic resonance (MR) ablation catheter.

Imricor said the FDA had approved its investigational device exception for the prospective, single-arm, multi-centre investigational study of the safety and efficacy of type I atrial flutter ablation procedures performed with the second-generation Vision-MR ablation catheter and the Osyka HAT 500 RF generator and irrigation pump.

The company said the study would include sites in the US and Europe with an interim analysis of the results after 76 patients have achieved the seven-day follow-up, with a final follow-up at three months and enrolment to begin “around mid-year”.

Imricor executive chair Steve Wedan said the approval was “a huge milestone for Imricor, moving us one step closer to offering [interventional cardiac magnetic resonance]-guided ablation procedures to patients in the US”.

Imricor was unchanged at 27 cents.

### CRESO PHARMA

Creso says its Canadian subsidiary Mernova Medical has secured a \$350,245 marijuana order, its largest to date, and has expanded into Manitoba.

Creso said the \$350,245 order from Nova Scotia Liquor Corporation was the largest purchase order secured from any province to date.

The company said “the value of the purchase order highlights the ongoing demand Creso Pharma is witnessing for its high-quality recreational cannabis products and will underpin revenue growth during 2022-’23”.

Creso said Mernova had expanded into Manitoba province which had about 170 retail marijuana shops.

Creso was up 0.2 cents or 10 percent to 2.2 cents with 7.2 million shares traded.

## GENETIC TECHNOLOGIES

Genetic Technologies says it has improved the performance of its Genetype colorectal cancer risk prediction

Genetic Technologies said that the test improved performance, identifying patients at risk of developing colorectal cancer by expanding the number of single nucleotide polymorphisms (SNPs) from 45 to 144, with patients in the top colorectal cancer risk category showing a 27 percent improvement compared with the 45 SNP Genetype.

The company said that the improved performance “was consistent across multiple genetic ancestries, greatly improving the utility of the test leading to increased surveillance in high-risk patients”.

Genetic Technologies said the data was presentation as a poster, titled ‘Improvement of a clinical colorectal cancer risk prediction model integrating polygenic risk’ by Dr Erika Speath at the American Society of Clinical Oncology Gastroenterology Cancer meeting in San Francisco, last weekend.

The company said that the poster built on an earlier publication that validated the Genetype model.

Genetic Technologies said that using SNPs for colorectal cancer risk stratification could “be crucial to improving screening and risk-reducing recommendations, and consequently does better than a one-size-fits-all screening regimen”.

The company said that current screening guidelines in the UK, US and Australia “focus solely on family history and age for risk prediction”.

“Unfortunately, the vast majority of the population do not have any hereditary or familial history and would remain unaware that they could be at elevated risk of developing colorectal cancer,” the company said.

Genetic Technologies was unchanged at 0.3 cents.

## PROBIOTEC

Pie Funds Management says it has ceased its substantial holding in Probiotec selling 67,480 shares between November 30, 2022 and January 23, 2023.

The Auckland, New Zealand-based Pie Funds said that it sold the shares at prices ranging from \$2.22 to \$2.30 a share.

Last month, Pie Funds said it had 4,130,203 Probiotec shares (5.08%) (BD: Dec 2, 2022). Probiotec was up one cent or 0.45 percent to \$2.22.

## KAZIA THERAPEUTICS

Willoughby Capital Trust says it has increased its holding in Kazia from 19,220,000 shares to 30,112,339 shares, but has been diluted from 16.1 percent to 15.95 percent.

The Sydney-based Willoughby Capital said that on January 16, 2023 it bought 8,462,339 shares for \$1,000,000, or 11.8 cents per share.

Last week, Kazia said it had raised \$4.5 million in a placement at 11.0 cents a share and opened a share purchase plan (BD: Jan 22, 2023).

A Kazia official told Biotech Daily that Willoughby bought \$1,000,000 of shares at 11 cents a share, or 9,090,909 shares, with the second tranche balance pending shareholder approval; and acquired 2,430,000 shares subsequent to the previous substantial shareholder notice.

Kazia was up one cent or 8.3 percent to 13 cents.

### ADALTA

Yuuwa Capital says its Innovation Investment Fund is winding up and has transferred its 54,059,848 Adalta shares to two unnamed investors associated with the fund.

In 2016, Yuuwa said it held 54,059,848 shares (54.06%) in Adalta, which had listed on the ASX the day previous (BD: Aug 22, 23, 2016).

In 2021, Yuuwa said its 54,059,848 share-holding in Adalta had been diluted from 22.05 percent to 18.2 percent (BD: Jan 16, 2022).

Today, Adalta said that the transfer of shares was part of Yuuwa Capital's end-of-fund wind-up, with the shares transferred off-market to two undisclosed substantial shareholders associated with Yuuwa Capital.

Adalta was untraded at 3.8 cents.

### RHINOMED

Rhinomed says it will increase managing-director Michael Johnson's base salary including superannuation, by 15.4 percent to \$375,000 a year, backdated to July 1, 2022.

Mr Johnson told Biotech Daily that his previous base rate salary was \$325,000 a year.

Rhinomed said that it increased Mr Johnson's base salary following "an external benchmarking process" and Mr Johnson had the potential to be paid up-to \$150,000 in short-term incentives, subject to a range of targets.

Rhinomed was unchanged at 10.5 cents.

### HERAMED

Heramed says it has appointed Keith Koby as its North America head.

Heramed said that Mr Koby was previously Nanosonics head of North America and had 30 years of experience in medical technology and devices.

The company said Mr Koby would be responsible for increasing Heramed's presence and establishing sales and distribution in North America.

Heramed fell one cent or 6.7 percent to 14 cents.